ClinicalTrials.gg
CompletedNCT05422365Updated Sep 23, 2024Results posted

Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults

A Phase 3 interventional study of Intravenous immunoglobulin (IVIG), 10% solution for infusion in Primary Immune Thrombocytopenia, sponsored by Biopharma Plasma LLC. Completed at 12 sites in Ukraine. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Biopharma Plasma LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
10th of 13
32 · median 40
Started
2022
with 1 other
Phase 3
9 of 13
1 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Biopharma Plasma LLC

Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 10th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The study will involve patients with chronic immune thrombocytopenia. This disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months.

Patients included in the study will receive Bioven, 10% solution for infusion according to the protocol for the use of IVIG in ITP - at a dose of 0.8-1.0 g / kg 1 time per day for 2 consecutive days, the course dose of 1.6-2.0 g / kg according to the "Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)", rev. 3, 28 June 2018. After administration of the investigational drug, patients will be under medical supervision for 28 days.

The stay of patients in the study - at least 4 weeks.

Read the detailed description

The investigational drug, IVIG, is used for immunomodulatory therapy in the treatment of autoimmune diseases.

The study will involve patients with chronic immune thrombocytopenia. This autoimmune disease is diagnosed in the presence of isolated thrombocytopenia (decrease in platelet count only), except for other reasons. The addition of "chronic" means that the disease lasts more than 12 months.

Screening stage The patient or her legal representative must sign an informed consent. After the informed consent signing procedure, the patient is screened and assessed for compliance with the inclusion and non-inclusion (exclusion) criteria.

Clinical stage After the patient is included in the study, according to the protocol, he/she is hospitalized and the study drug is administered at a dose of 0.8-1.0 g/kg once a day for 2 days (the course dose is 1.6-2.0 g/kg). The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG) and the Coombs test. This procedure will also be carried out on days 7, 14, 21 and 28 after the first injection of the drug to monitor the patient's performance.

The final stage The blood sampling procedure to determine the above indicators will be carried out on days 7, 14, 21, and 28 after the first administration of the drug to monitor the patient's performance.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • IVIG
  • ITP
  • immunomodulatory therapy
  • intravenous immunoglobulin
  • chronic primary immune thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Patient Form for participation in the study;
  • Men and women aged 18-65;
  • Confirmed primary chronic ITP (lasting > 12 months since diagnosis);
  • A full blood count should be normal except for the isolated thrombocytopenia. Patients with low levels (but above 90 g / l) may be included if there are symptoms of bleeding;
  • If bleeding symptoms are diagnosed, the reticulocyte count should be measured;
  • count \<30 x 109 / L;
  • If the patient is taking , the treatment regimen/dose should be stable (at least 2 weeks prior to screening);
  • Negative pregnancy test (for women of );
  • Willingness to use effective and reliable methods of throughout the entire study period;
  • The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;
  • Ability, according to the researcher, to follow all the requirements of the study protocol;

Exclusion criteria

Exclusion criteria:

  • Known intolerance to plasma and immunoglobulin preparations;
  • Drug allergy or to immunoglobulin preparations;
  • Confirmed deficiency of immunoglobulin A (IgA) and antibodies to IgA.
  • to immunoglobulin administration according to the instructions for medical use;
  • Pregnancy and lactation;
  • Any hepatic impairment (increase of serum transaminase levels by more than 3 times the );
  • Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;
  • Severe cardiovascular insufficiency (HF III);
  • History of thrombosis or presence of significant risk factors for thrombosis.
  • Patients with preventive splenectomy;
  • Hemostatic disorders other than chronic thrombocytopenia;
  • Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;
  • Proven case of primary immunodeficiency;
  • Secondary immune thrombocytopenia;
  • Virus infections (Epstein-Barr, Cytomegalovirus, Parvovirus, and C);
  • Documented infection
  • Positive reaction of Wassermann (RW) test result;
  • Systemic immunopathological diseases (rheumatic diseases, nephritis, etc.);
  • Oncological diseases;
  • Diabetes mellitus;
  • Thyroid diseases;
  • History of mental illness;
  • Known drug addiction;
  • Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;
  • The need to prescribe drugs that are incompatible with the administration of the drug in this study: other immunoglobulin preparations in addition to the study drug, cytostatic drugs, monoclonal antibodies, Avatrombopag);
  • Experimental treatment (e.g. Rituximab therapy) for 3 months prior to screening);
  • Blood transfusions or transfusions of blood products in the last 6 months prior to inclusion in the study;
  • Administration of IVIG 30 days prior to screening;
  • Participation in any other study currently or within the last 30 days;

Criteria for exclusion of subjects (discontinuation of treatment with the study drug):

  • Patient's wish
  • Occurrence of severe and/or unexpected Adverse events (AE) or Adverse reactions (AR) in patient during the study, that require discontinuation of the drug;
  • The need to prescribe drugs prohibited in this study.
  • Significant deterioration of the patient's condition during the study period;
  • Failure of the patient to adhere to the treatment regimen;
  • Failure of the patient to follow the procedures established under the protocol;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Main Group

    Patients included in the study will receive the intravenous immunoglobulin (IVIG, Bioven), 10% solution for infusion according to the protocol for the use of IVIG in ITP treatment - at a dose of 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg. The next day after the administration of the drug, the patient undergoes blood sampling to determine the level of platelets, the level of immunoglobulin G (IgG), and the Coombs test. This procedure will also be carried out on days 7, 14, 21, and 28 after the first injection of the drug to monitor the patient's performance.

    Drug: Intravenous immunoglobulin (IVIG), 10% solution for infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Part (Percent) of Patients With Response (R)

    platelet count \>30 x 109 /l and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding

    Time frame: 28 days after first administration of the study drug

Secondary outcomes

  1. Part (Percent) of Patients With Complete Response (CR)

    platelet count \>100 x 109 /l, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding. Complete response (CR) was achieved in 13 patients during the study. CR = 13/32 = 40.63 % (23,61%; 57,64%) This corresponds 40,63% from total number of patients. The confidence interval for this value is 23.61% to 57.64%

    Time frame: 28 days after first administration of the study drug

  2. Part (Percent) of Patients With no Response (NR)

    platelet count \< 30 x 109/L or less than a 2-fold increase of the baseline count. It should be confirmed by at least 2 blood tests or presence of bleeding

    Time frame: 28 days after first administration of the study drug

  3. Part (Percent) of Patients With Loss of Response (R)

    Decreasing platelet count (\< 30 x 109/L or less than a 2-fold increase of the baseline count) or development of bleeding. Platelet count should be confirmed at least two times, with an interval of 1 day.

    Time frame: 28 days after first administration of the study drug

  4. Part (Percent) of Patients With Loss of Complete Response (CR)

    decreased platelet count \<100 x 109/L or development of bleeding

    Time frame: 28 days after first administration of the study drug

  5. Time (in Days) From Treatment Start to Response (R)

    Time calculated from first infusion (treatment start) to the day when the response (R) criteria are achieved

    Time frame: 28 days after first administration of the study drug

  6. Time (in Days) From Treatment to Complete Response (CR)

    Time calculated from first infusion (treatment start) to the day when the complete response (CR) criteria are achieved

    Time frame: 28 days after first administration of the study drug

  7. Duration (in Days) of Response (R)

    Time calculated from the day when the complete response (R) criteria are achieved, to the day when loss of complete response (R) criteria is achieved

    Time frame: 28 days after first administration of the study drug

  8. Duration (in Days) of Complete Response (CR)

    Time calculated from the day when the complete response (CR) criteria are achieved, to the day when loss of complete response (CR) criteria are achieved

    Time frame: 28 days after first administration of the study drug

Other outcomes

  1. Frequency (Percent) of Adverse Events

    Part of the drug administration cases with adverse events, from all cases of study drug administration

    Time frame: 28 days after first administration of the study drug

  2. Frequency of Serious Adverse Events

    Part of the drug administration cases with serious adverse events, from all cases of study drug administration

    Time frame: 28 days after first administration of the study drug

07

Results

Posted Sep 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneMain Group
Started32
Completed32
Not completed0

Outcome measures

PrimaryPart (Percent) of Patients With Response (R)

platelet count \>30 x 109 /l and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding

Time frame:
28 days after first administration of the study drug
Reported as:
Count of participants · Participants
Part (Percent) of Patients With Response (R)
ParticipantsMain Group
Part (Percent) of Patients With Response (R)24
SecondaryPart (Percent) of Patients With Complete Response (CR)

platelet count \>100 x 109 /l, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding. Complete response (CR) was achieved in 13 patients during the study. CR = 13/32 = 40.63 % (23,61%; 57,64%) This corresponds 40,63% from total number of patients. The confidence interval for this value is 23.61% to 57.64%

Time frame:
28 days after first administration of the study drug
Reported as:
Number · percentage of participants
Part (Percent) of Patients With Complete Response (CR)
percentage of participantsMain Group
Part (Percent) of Patients With Complete Response (CR)40.63 (23.61 to 57.64)
SecondaryPart (Percent) of Patients With no Response (NR)

platelet count \< 30 x 109/L or less than a 2-fold increase of the baseline count. It should be confirmed by at least 2 blood tests or presence of bleeding

Time frame:
28 days after first administration of the study drug
Reported as:
Number · percentage of participants
Part (Percent) of Patients With no Response (NR)
percentage of participantsMain Group
Part (Percent) of Patients With no Response (NR)25 (9.99 to 40)
SecondaryPart (Percent) of Patients With Loss of Response (R)

Decreasing platelet count (\< 30 x 109/L or less than a 2-fold increase of the baseline count) or development of bleeding. Platelet count should be confirmed at least two times, with an interval of 1 day.

Time frame:
28 days after first administration of the study drug
Reported as:
Number · percentage of participants
Part (Percent) of Patients With Loss of Response (R)
percentage of participantsMain Group
Part (Percent) of Patients With Loss of Response (R)31.25 (15.19 to 47.31)
SecondaryPart (Percent) of Patients With Loss of Complete Response (CR)

decreased platelet count \<100 x 109/L or development of bleeding

Time frame:
28 days after first administration of the study drug
Reported as:
Count of participants · Participants
Part (Percent) of Patients With Loss of Complete Response (CR)
ParticipantsMain Group
Part (Percent) of Patients With Loss of Complete Response (CR)13
SecondaryTime (in Days) From Treatment Start to Response (R)

Time calculated from first infusion (treatment start) to the day when the response (R) criteria are achieved

Time frame:
28 days after first administration of the study drug
Reported as:
Median · days
Time (in Days) From Treatment Start to Response (R)
daysMain Group
Time (in Days) From Treatment Start to Response (R)2 (2 to 3)
SecondaryTime (in Days) From Treatment to Complete Response (CR)

Time calculated from first infusion (treatment start) to the day when the complete response (CR) criteria are achieved

Time frame:
28 days after first administration of the study drug
Reported as:
Median · days
Time (in Days) From Treatment to Complete Response (CR)
daysMain Group
Time (in Days) From Treatment to Complete Response (CR)2 (2 to 4)
SecondaryDuration (in Days) of Response (R)

Time calculated from the day when the complete response (R) criteria are achieved, to the day when loss of complete response (R) criteria is achieved

Time frame:
28 days after first administration of the study drug
Reported as:
Median · days
Duration (in Days) of Response (R)
daysMain Group
Duration (in Days) of Response (R)27 (25 to 29)
SecondaryDuration (in Days) of Complete Response (CR)

Time calculated from the day when the complete response (CR) criteria are achieved, to the day when loss of complete response (CR) criteria are achieved

Time frame:
28 days after first administration of the study drug
Reported as:
Median · days
Duration (in Days) of Complete Response (CR)
daysMain Group
Duration (in Days) of Complete Response (CR)19 (13 to 25)
Other pre-specifiedFrequency (Percent) of Adverse Events

Part of the drug administration cases with adverse events, from all cases of study drug administration

Time frame:
28 days after first administration of the study drug
Reported as:
Count of participants · Participants
Frequency (Percent) of Adverse Events
ParticipantsMain Group
Frequency (Percent) of Adverse Events4
Other pre-specifiedFrequency of Serious Adverse Events

Part of the drug administration cases with serious adverse events, from all cases of study drug administration

Time frame:
28 days after first administration of the study drug
Reported as:
Count of participants · Participants
Frequency of Serious Adverse Events
ParticipantsMain Group
Frequency of Serious Adverse Events1

Adverse events

Collected over 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Group0/32 (0%)1/32 (3.1%)4/32 (12.5%)
Most frequent serious events
Most frequent serious events
EventMain Group
Vein thrombosisBlood and lymphatic system disorders1/32
Most frequent other events
Most frequent other events
EventMain Group
HeadacheNervous system disorders3/32
Allergic reactionGeneral disorders1/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Main Group
<=18 years0
Between 18 and 65 years32
>=65 years0
Age, Continuous
Age, Continuous(years)Main Group
Median41 (18 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Main Group
Female25
Male7
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Main Group
Region of Enrollment
Region of Enrollment(participants)Main Group
Ukraine26
Turkey6
08

Study locations

12 sites
  • Municipal non-profit enterprise "City Clinical Hospital No. 4" of the Dnipro City Council
    Dnipro, 49102, Ukraine
  • Municipal non-profit enterprise "Khmelnytskyi Regional Hospital" of the Khmelnytskyi Regional Council
    Khmelnytskyi, 29010, Ukraine
  • Municipal Non-Profit Enterprise "Kirovohrad Regional Hospital of the Kirovohrad Regional Council"
    Kropyvnytskyi, 25030, Ukraine
  • Medical Center "OK!Clinic+" of the Company with Limited Liability "International Institute of Clinical Research"
    Kyiv, 02091, Ukraine
  • Municipal Non-Profit Enterprise of Kyiv Regional Council "Kyiv Regional Oncology Dispensary"
    Kyiv, 04107, Ukraine
  • Municipal non-profit enterprise "Kyiv City Clinical Hospital No. 9" of the executive body of the Kyiv City Council (Kyiv City State Administration)
    Kyiv, 04112, Ukraine
  • "Arensia Exploratory Medicine" Limited Liability Company Medical Center
    Kyiv, 08112, Ukraine
  • State Institution "Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine"
    Lviv, 79044, Ukraine
  • Minicipal enterprise "Rivne regional clinical hospital" of Rivne regional council
    Rivne, 33007, Ukraine
  • Municipal Non-Profit Enterprise of Sumy Regional Council "Sumy Regional Clinical Hospital"
    Sumy, 40031, Ukraine
  • Municipal non-profit enterprise "Ternopil University Hospital" of Ternopil Regional Council
    Ternopil, 46002, Ukraine
  • Municipal Non-Profit Enterprise "Zakarpattia Regional Clinical Hospital named after Andriy Novak" of Zakarpattia Regional Council
    Uzhhorod, 88000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The results will be published after trial completion. Access to parts of the Clinical Study Report (CSR) planned after the release of scientific publications. Individual participant data (IPD) with the code of each patient will be available In CSR

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After the scientific publication of trial results, 3 months later

Access criteria: For specialists in field medicine, pharmacy, scientists

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2023, 16 months.

Results were first posted in Sep 2024, 9 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 16 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 16, 2022
StartActual
Jul 26, 2022
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Results first posted
Sep 23, 2024
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05422365
Lead sponsor
Biopharma Plasma LLC
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Jul 26, 2022
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Results posted
Sep 23, 2024
Last update
Sep 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion